Inhaled insulin: A breath of fresh air? a review of inhaled insulin

Clinical Therapeutics

Volumn 36, Issue 8, 2014, Pages 1275-1289

  Santos Cavaiola, Tricia ^a   Edelman, Steven ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

diabetes; glycemic control; inhalation; inhaled; insulin; pulmonary

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; PIG INSULIN; RECOMBINANT HUMAN INSULIN; TECHNOSPHERE INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ACUTE RESPIRATORY TRACT DISEASE; ANTIDIABETIC ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INHALER; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG CANCER; LUNG FUNCTION; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PATIENT PREFERENCE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SYSTEMATIC REVIEW; WEIGHT GAIN; DIABETES MELLITUS; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; DIABETES MELLITUS; FORCED EXPIRATORY VOLUME; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84906936347     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.06.025     Document Type: Review

References (52)

1. A.H. Boss, W. Yu, and K. Ellerman Prandial insulin: is inhaled enough? Drug Development Research 69 2008 138 142
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
3. G.T. McMahon, and R.A. Arky Inhaled insulin for diabetes mellitus N Engl J Med 356 2007 497 502
4. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years BMJ 14 1995 83 85
5. W.H. Polonsky, L. Fisher, and S. Guzman et al. Psychological insulin resistance in patients with type 2 diabetes Diabetes Care 28 2005 2543 2545
6. M. Gansslen Uber inhalation von insulin Klin Wochenschr 4 1925 71
7. L. Heinemann Alternative delivery routes: inhaled insulin Diabetes Nutr Metab 15 2002 417 422
8. S. Yaturn Insulin therapies: current and future trends at dawn World J Diabetes 4 2013 1 7
9. W.T. Cefalu Concept, strategies, and feasibility of noninvasive insulin delivery Diabetes Care 27 2004 239 246
10. J.L. Selam Inhaled insulin: promises and concerns J Diab Sci Technology 2 2008 311 315
11. J.S. Patton Mechanism of macromolecule absorption by the lungs Adv Drug Deliv Rev 19 1996 3 36
12. O.S. Usmani, M.F. Biddiscombe, and P.J. Barnes Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size Am J Respir Crit Care Med 172 2005 1497 1504
13. I. Gonda Systemic delivery of drugs to humans via inhalation J Aerosol Med 19 2006 47 53
14. S. Mudaliar, and R.R. Henry Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease Diabetes Technol Ther Suppl 1 2007 S83 S92
15. L.D. Mastrandrea Inhaled insulin: overview of a novel route of insulin administration Vasc Health Risk Manag 6 2010 47 58
16. J.S. Patton, J.G. Bukar, and M.A. Eldon Clinical pharmacokinetics and pharmacodynamics of inhaled insulin Clin Pharmacokinet 43 2004 781 801
17. K. Rave, S. Bott, and L. Heinemann et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin Diabetes Care 28 2005 1077 1082
18. L. Ceglia, J. Lau, and A.G. Pittas Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus Ann Intern Med 145 2006 665 675
19. S.M. Setter, T.L. Levien, and J.L. Iltz et al. Inhaled dry powder insulin for the treatment of diabetes mellitus Clin Ther 29 2007 795 813
20. Boss AH, Evans SH, Firsov I, et al. Technosphere®/insulin as effective as SC rapid acting insulin analogue in providing glycemic control in a 6-month study of patients with type 2 diabetes. Post presented at: Sixth Annual Diabetes Technology Meeting, November 2-4, 2006, Atlanta, GA.
21. J.S. Skyler, L. Jovanovic, and S. Klioze et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes Diabetes Care 30 2007 579 585
22. J. Rosentock, W.T. Cefalu, and P.A. Hollander et al. Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial Diabetes Technol Ther 11 2009 697 705
23. J.S. Skyler, P.A. Hollander, and L. Jovanovic et al. Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: a 3-year randomized controlled trial Diabetes Res Clin Pract 82 2008 238 246
24. A. Himmelmann, J. Jendle, and A. Mellen et al. The impact of smoking on inhaled insulin Diabetes Care 26 2003 677 682
25. S. Wise, J. Chien, and K. Yeo et al. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system Diabetes Med 23 2006 510 515
26. A. McElduff, L.E. Mather, and P.C. Kam et al. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System Br J Clin Pharmacol 59 2005 546 551
27. R. Fountaine, A. Milton, and G. Wei et al. FEV1 response to albuterol is not affected by inhaled human insulin (Exubera®) use in subjects with mild-to-moderate asthma Eur Respir J 28 Suppl 50 2006 840S
28. E. Potocka, N. Amin, and J. Cassidy et al. Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease Curr Med Res Opin 26 2010 2347 2353
29. www.fda.gov. Exubera (insulin human [rDNA origin]) Inhalation Powder. Safety Labeling Changes Approved by FDA Center for Drug Evaluation and Research. September 2008.
30. LaMattina J. Challenges in commercializing inhaled insulin. www.forbes.com. August 23, 2013.
31. P.C. Richardson, and A.H. Boss Technosphere® Insulin technology Diabetes Technol Ther 9 Suppl 1 2007 565 572
32. P. Raskin, S. Heller, and M. Honka et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial Diabetes Obes Metab 14 2011 163 173
33. TM drug carrier mechanism Expert Opin Drug Deliv 2 2005 1097 1106
34. Cassidy JP, Potocka E, Baughman RA, et al. Pharmacokinetic characterization of the Technosphere® Insulin Platform. Post presented at: Ninth Annual Diabetes Technology Meeting, November 5-7, 2009, San Francisco, CA.
35. J.J. Neumiller, and R.K. Campbell Technosphere® Insulin. An inhaled prandial insulin product Biodrugs 24 2010 165 172
36. rd Annual Scientific Sessions of the American Diabetes Association, June 21-25, 2013, Chicago, IL.
37. K. Rave, E. Potocka, and L. Heinemann et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin Diabetes Obes Metab 11 2009 715 720
38. A.H. Boss, R. Petrucci, and D. Lorber Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin J Diabetes Sci Technol 4 2012 773 779
39. R. Angelo, K. Rousseau, and M. Grant et al. Technosphere® insulin: defining the mechanism of action Diabetes Care 57 Suppl 1 2008 A128
40. S. Steiner, A. Pfützner, and B.R. Wilson et al. Technosphere/insulin - proof of concept study with a new insulin formulation for pulmonary delivery Exp Clin Endocrinol Diabetes 110 2002 17 21
41. TM suppresses endogenous glucose production earlier than a rapid acting analog (Lispro) and inhaled Exubera® Diabetes 58 Suppl 1 2009 A61
42. K. Rave, T. Heise, and L. Heinemann et al. Inhaled Technosphere Insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes J Diabetes Sci Technol 2 2008 205 212
43. J. Rosenstock, R. Bergestal, and R. DeFronzo et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents Diabetes Care 31 2008 2177 2182
44. K. Rave, T. Heise, and A. Pfützner et al. Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes Diabetes Care 30 2007 2307 2308
45. H. Zisser, L. Jovanovic, and K. Markova et al. Technosphere Insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus Diabetes Tech Therapeut 14 2012 1 5
46. C.J. Tack, V. Christo, and B. de Galan et al. Randomized forced titration to different doses of Technosphere® Insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes J Diabetes Sci Technol 2 2008 7 57
47. J. Rosenstock, D.L. Lorber, and L. Gnudi et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomized trial Lancet 375 2010 2244 2253
48. P. Kapsner, R.M. Bergenstal, and M. Rendell et al. Comparative efficacy and safety of Technosphere® Insulin and a rapid-acting analog both given with glargine in subjects with T1 DM in a 52-week study Diabetologia 52 Suppl 1 2009
49. R. Baughman, J. Cassidy, and B. Levy et al. Technosphere® Insulin inhalation powder pharmacokinetics unchanged in subjects who smoke Diabetes 57 Suppl 1 2008
50. R. Baughman, J. Cassidy, and N. Amin et al. A Phase 1, Open-label study of the effect of albuterol or fluticasone on the pharmacokinetics of inhaled Technosphere® Insulin inhalation powder in healthy subjects Diabetes 59 Suppl 1 2010
51. J.P. Cassidy, N. Amin, and R. Baughman et al. Insulin Kinetics Unchanged in Albuterol Treated Asthmatics Following Technosphere® Insulin Inhalation Powder Administration Diabetes 59 Suppl 1 2010
52. M. Peyrot, and R.R. Rubin Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction Diabetes Technol Ther 12 2010 49 55